Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

GLOFITAMAB-GXBM: 498 Adverse Event Reports & Safety Profile

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now
498
Total FAERS Reports
175 (35.1%)
Deaths Reported
113
Hospitalizations
498
As Primary/Secondary Suspect
24
Life-Threatening
5
Disabilities
Prescription
Status

FDA Application: 761309 ·

First Report: 20180601 · Latest Report: 20250915

What Are the Most Common GLOFITAMAB-GXBM Side Effects?

#1 Most Reported
Cytokine release syndrome
107 reports (21.5%)
#2 Most Reported
Off label use
68 reports (13.7%)
#3 Most Reported
Disease progression
68 reports (13.7%)

All GLOFITAMAB-GXBM Side Effects by Frequency

Side Effect Reports % of Total Deaths Hosp.
Cytokine release syndrome 107 21.5% 16 41
Disease progression 68 13.7% 40 13
Off label use 68 13.7% 9 17
Death 67 13.5% 67 6
Pyrexia 45 9.0% 12 8
No adverse event 28 5.6% 0 0
Immune effector cell-associated neurotoxicity syndrome 25 5.0% 13 18
Infection 20 4.0% 11 13
Pneumonia 14 2.8% 9 3
Condition aggravated 12 2.4% 11 0
Covid-19 10 2.0% 4 3
Drug ineffective 10 2.0% 4 2
Sepsis 10 2.0% 5 5
Diffuse large b-cell lymphoma recurrent 9 1.8% 0 1
Dyspnoea 9 1.8% 2 5
Hyperpyrexia 9 1.8% 1 1
Myelosuppression 9 1.8% 2 3
Acute myeloid leukaemia 8 1.6% 2 0
Febrile neutropenia 8 1.6% 0 4
Hypotension 8 1.6% 1 2

Who Reports GLOFITAMAB-GXBM Side Effects? Age & Gender Data

Gender: 36.2% female, 63.8% male. Average age: 60.0 years. Most reports from: CN. View detailed demographics →

Is GLOFITAMAB-GXBM Getting Safer? Reports by Year

YearReportsDeathsHosp.
2018 1 1 0
2021 1 1 0
2023 24 6 10
2024 96 31 22
2025 56 20 29

View full timeline →

What Is GLOFITAMAB-GXBM Used For?

IndicationReports
Diffuse large b-cell lymphoma 313
Product used for unknown indication 55
Diffuse large b-cell lymphoma refractory 38
B-cell lymphoma 20
Mantle cell lymphoma 18
Diffuse large b-cell lymphoma recurrent 10
Follicular lymphoma 7
Burkitt's lymphoma 6
Lymphoma 6
Lymphoma transformation 5

GLOFITAMAB-GXBM vs Alternatives: Which Is Safer?

GLOFITAMAB-GXBM vs GLUCAGON GLOFITAMAB-GXBM vs GLUCAGON\GLUCAGON\WATER GLOFITAMAB-GXBM vs GLUCARPIDASE GLOFITAMAB-GXBM vs GLUCOPHAGE GLOFITAMAB-GXBM vs GLUCOSAMINE GLOFITAMAB-GXBM vs GLUTAMINE GLOFITAMAB-GXBM vs GLUTATHIONE GLOFITAMAB-GXBM vs GLYBURIDE GLOFITAMAB-GXBM vs GLYBURIDE\METFORMIN GLOFITAMAB-GXBM vs GLYCERIN

Official FDA Label for GLOFITAMAB-GXBM

Official prescribing information from the FDA-approved drug label.